Breakout Setups
LMAT appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
LEMAITRE VASCULAR INC (LMAT) Stock Price & Overview
NASDAQ:LMAT • US5255582018
Current stock price
113.17 USD
+1.27 (+1.13%)
Last:
The current stock price of LMAT is 113.17 USD. Today LMAT is up by 1.13%. In the past month the price increased by 3.75%. In the past year, price increased by 22.15%.
LMAT Key Statistics
52-Week Range78.0101 - 118.01
Current LMAT stock price positioned within its 52-week range.
1-Month Range104.14 - 118.01
Current LMAT stock price positioned within its 1-month range.
- Market Cap
- 2.578B
- P/E
- 47.55
- Fwd P/E
- 38.22
- EPS (TTM)
- 2.38
- Dividend Yield
- 0.90%
LMAT Stock Performance
Today
+1.13%
1 Week
-4.68%
1 Month
+3.75%
3 Months
+32.87%
Longer-term
6 Months +25.43%
1 Year +22.15%
2 Years +72.69%
3 Years +107.22%
5 Years +113.26%
10 Years +574.91%
LMAT Stock Chart
LMAT Stock Screens
LMAT currently appears in the following ChartMill screener lists.
LMAT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LMAT. When comparing the yearly performance of all stocks, LMAT is one of the better performing stocks in the market, outperforming 82.3% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
LMAT Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to LMAT. LMAT gets an excellent profitability rating and is at the same time showing great financial health properties.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LMAT Earnings
On February 25, 2026 LMAT reported an EPS of 0.68 and a revenue of 64.45M. The company beat EPS expectations (0.42% surprise) and beat revenue expectations (0.58% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.68
Revenue Reported64.453M
EPS Surprise 0.42%
Revenue Surprise 0.58%
LMAT Forecast & Estimates
16 analysts have analysed LMAT and the average price target is 113.07 USD. This implies a price decrease of -0.08% is expected in the next year compared to the current price of 113.17.
For the next year, analysts expect an EPS growth of 24.41% and a revenue growth 12.71% for LMAT
Analysts
Analysts80
Price Target113.07 (-0.09%)
EPS Next Y24.41%
Revenue Next Year12.71%
LMAT Groups
Sector & Classification
LMAT Financial Highlights
Over the last trailing twelve months LMAT reported a non-GAAP Earnings per Share(EPS) of 2.38. The EPS increased by 22.68% compared to the year before.
Income Statements
Revenue(TTM)249.60M
Net Income(TTM)57.73M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.13% | ||
| ROA | 9.38% | ||
| ROE | 14.67% | ||
| Debt/Equity | 0.43 |
Chartmill High Growth Momentum
EPS Q2Q%38.78%
Sales Q2Q%15.68%
EPS 1Y (TTM)22.68%
Revenue 1Y (TTM)13.53%
LMAT Ownership
Ownership
Inst Owners95.94%
Shares22.78M
Float21.27M
Ins Owners7.04%
Short Float %6.3%
Short Ratio5.67
LMAT Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 14.65 | 161.117B | ||
| ISRG | INTUITIVE SURGICAL INC | 41.74 | 160.285B | ||
| SYK | STRYKER CORP | 21.84 | 125.349B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.63 | 88.457B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.03 | 45.956B | ||
| IDXX | IDEXX LABORATORIES INC | 38.91 | 45.191B | ||
| BDX | BECTON DICKINSON AND CO | 11.36 | 44.616B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.76 | 32.972B | ||
| RMD | RESMED INC | 18.14 | 32.227B | ||
| DXCM | DEXCOM INC | 24.78 | 24.092B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.01 | 17.942B | ||
| PODD | INSULET CORP | 29.99 | 13.321B | ||
| PEN | PENUMBRA INC | 65.28 | 12.858B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LMAT
Company Profile
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 646 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
Company Info
IPO: 2006-10-19
LEMAITRE VASCULAR INC
63 2nd Ave
Burlington MASSACHUSETTS 01803 US
CEO: George W. LeMaitre
Employees: 651
Phone: 18009279800
LEMAITRE VASCULAR INC / LMAT FAQ
What does LEMAITRE VASCULAR INC do?
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 646 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
What is the stock price of LEMAITRE VASCULAR INC today?
The current stock price of LMAT is 113.17 USD. The price increased by 1.13% in the last trading session.
What is the dividend status of LEMAITRE VASCULAR INC?
LEMAITRE VASCULAR INC (LMAT) has a dividend yield of 0.9%. The yearly dividend amount is currently 0.8.
What is the ChartMill technical and fundamental rating of LMAT stock?
LMAT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is LMAT stock listed?
LMAT stock is listed on the Nasdaq exchange.
How is the valuation of LEMAITRE VASCULAR INC (LMAT) based on its PE ratio?
The PE ratio for LEMAITRE VASCULAR INC (LMAT) is 47.55. This is based on the reported non-GAAP earnings per share of 2.38 and the current share price of 113.17 USD.
Can you provide the ownership details for LMAT stock?
You can find the ownership structure of LEMAITRE VASCULAR INC (LMAT) on the Ownership tab.